Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women.
Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women.
- 2018
BACKGROUND: Vasomotor symptoms may be markers of changes in cardiovascular risk, but it is unknown whether these symptoms are associated with the risk of venous thrombosis (VT). CONCLUSIONS: Although vasomotor symptoms have been associated with the risk of other cardiovascular events in published studies, our findings do not suggest that vasomotor symptoms are a marker of VT risk. This article is protected by copyright. All rights reserved. Copyright This article is protected by copyright. All rights reserved. METHODS: This cohort study included participants of the Women's Health Initiative (WHI) Hormone Therapy Trials (n=24,508) and Observational Study (n=87,783), analyzed separately. At baseline, women reported whether hot flashes or night sweats were present and if so, their severity. Using Cox proportional hazards models, we estimated VT risk associated with vasomotor symptom presence and severity, adjusted for potential explanatory variables: age, BMI, smoking status, race/ethnicity, and time-varying current hormone therapy use. OBJECTIVE: To evaluate the association of vasomotor symptom presence and severity with incident VT risk among postmenopausal women, independent of potential explanatory variables. RESULTS: At baseline, WHI Hormone Therapy Trial participants were 64 years of age and WHI Observational Study participants were 63 years of age, on average. In the WHI Hormone Therapy Trials over a median of 8.2 years of follow-up, 522 women experienced a VT event. In the WHI Observational Study, over 7.9 years of follow-up, 1,103 women experienced a VT event. In adjusted analyses, we found no evidence of an association between vasomotor symptom presence (HRadj =0.91 [95%CI: 0.75, 1.1] in WHI Hormone Therapy Trials; HRadj =1.1 [95%CI: 0.99, 1.3] in WHI Observational Study) or severity (HRadj for severe vs. mild=0.99 [95%CI: 0.53, 1.9] in WHI Hormone Therapy Trials; HRadj =1.3 [95%CI: 0.89, 2.0] in WHI Observational Study) and the risk of incident VT.
English
1538-7836
10.1111/jth.13993 [doi]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Medicine/Endocrinology
Journal Article
BACKGROUND: Vasomotor symptoms may be markers of changes in cardiovascular risk, but it is unknown whether these symptoms are associated with the risk of venous thrombosis (VT). CONCLUSIONS: Although vasomotor symptoms have been associated with the risk of other cardiovascular events in published studies, our findings do not suggest that vasomotor symptoms are a marker of VT risk. This article is protected by copyright. All rights reserved. Copyright This article is protected by copyright. All rights reserved. METHODS: This cohort study included participants of the Women's Health Initiative (WHI) Hormone Therapy Trials (n=24,508) and Observational Study (n=87,783), analyzed separately. At baseline, women reported whether hot flashes or night sweats were present and if so, their severity. Using Cox proportional hazards models, we estimated VT risk associated with vasomotor symptom presence and severity, adjusted for potential explanatory variables: age, BMI, smoking status, race/ethnicity, and time-varying current hormone therapy use. OBJECTIVE: To evaluate the association of vasomotor symptom presence and severity with incident VT risk among postmenopausal women, independent of potential explanatory variables. RESULTS: At baseline, WHI Hormone Therapy Trial participants were 64 years of age and WHI Observational Study participants were 63 years of age, on average. In the WHI Hormone Therapy Trials over a median of 8.2 years of follow-up, 522 women experienced a VT event. In the WHI Observational Study, over 7.9 years of follow-up, 1,103 women experienced a VT event. In adjusted analyses, we found no evidence of an association between vasomotor symptom presence (HRadj =0.91 [95%CI: 0.75, 1.1] in WHI Hormone Therapy Trials; HRadj =1.1 [95%CI: 0.99, 1.3] in WHI Observational Study) or severity (HRadj for severe vs. mild=0.99 [95%CI: 0.53, 1.9] in WHI Hormone Therapy Trials; HRadj =1.3 [95%CI: 0.89, 2.0] in WHI Observational Study) and the risk of incident VT.
English
1538-7836
10.1111/jth.13993 [doi]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Medicine/Endocrinology
Journal Article